IBRX270319C00008000
IBRX Mar 19 2027 8.00 Call
optionOPRA
EODOct 16, 2026
3.00USD-11.765%(-0.40)59Vol1,300OI
Loading…
Underlying
Underlying Price
$8.28
Type
Call
Strike
8
Expiration
Mar 19, 2027
DTE
150d
Moneyness
ITM
Intrinsic
$0.28
IBRX 8 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $2.17 | +3.33% | 11 | 457 |
| Oct 30, 2026 | 10d | $1.42 | -29.00% | 8 | 45 |
| Nov 6, 2026 | 17d | $1.85 | -31.23% | 10 | 507 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $1.75 | -28.57% | 129 | 1,390 |
| Nov 27, 2026 | 38d | $1.90 | -25.49% | 2 | 11 |
| Dec 18, 2026 | 59d | — | — | 0 | 17 |
| Mar 19, 2027 | 150d | $3.00 | -11.76% | 59 | 1,300 |
| Apr 16, 2027 | 178d | $4.16 | +69.80% | 20 | 96 |
| May 21, 2027 | 213d | $3.00 | +13.21% | 2 | 4 |
IBRX Nearby Strikes · Mar 19, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2 C | $5.35 | +0.00% | 210 | 210 | ITM |
| 3 C | $5.73 | +8.11% | 10 | 709 | ITM |
| 4 C | $6.49 | -3.99% | 223 | 236 | ITM |
| 5 C | $5.40 | +0.93% | 15 | 350 | ITM |
| 6 C | $4.45 | -3.26% | 2 | 17 | ITM |
| 7 C | $4.03 | -4.05% | 1 | 255 | ITM |
| 8 C | $3.00 | -11.76% | 59 | 1,300 | ITM |
| 9 C | $2.30 | -24.09% | 73 | 428 | OTM |
| 10 C | $2.20 | -21.43% | 192 | 1,352 | OTM |
| 11 C | $1.60 | -41.82% | 11 | 921 | OTM |
| 12 C | $1.40 | -31.71% | 3 | 380 | OTM |
| 13 C | $2.00 | +42.86% | 5 | 23 | OTM |
| 14 C | $1.50 | -25.74% | 5 | 35 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.